Hyperthermia for non-muscle invasive bladder cancer.
Expert Rev Anticancer Ther
; 16(3): 313-21, 2016.
Article
en En
| MEDLINE
| ID: mdl-26713510
ABSTRACT
Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Calmette Guerin (BCG)-failures. Chemohyperthermia (CHT) has been tested as adjuvant therapy in selected categories of patients with promising results. The aim of this systematic review is to explore the current role of CHT and its future perspectives. The review process was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. After the selection process, 30 articles were used in this review. Treatment with CHT is safe and quite well tolerated. CHT seems to be effective in low and intermediate risk bladder cancer. Moreover CHT could be offered to selected categories of high risk patients and BCG failures NMIBC. Further trials are needed in order to better identify the categories of patients which could benefit from this therapy and to standardise the right schedule of treatment.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Vejiga Urinaria
/
Hipertermia Inducida
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Rev Anticancer Ther
Asunto de la revista:
NEOPLASIAS
/
TERAPEUTICA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Italia